Mojtaba Akhtari, MD
Hematology & Oncology · Omaha, NENPI 1922286954
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,599,003 of the $1,817,035 with a category attached, or 88.0%. 45 manufacturers reported payments, led by Incyte Corporation at 24.2% of the total. 2025 is the largest year on record at $481,067, more than ten times the $47,913 reported in 2019. Among hematology & oncology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,167 payments — averaging $1557.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$440K
- E.r. Squibb & Sons, L.L.C.$173K
- Karyopharm Therapeutics Inc.$142K
- Sobi, Inc$133K
- Sanofi$100K
- Pharmaessentia USA Corporation$94K
- plus $735K from 39 others
Across 23 payments — averaging $4506.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$36K
- Amgen$29K
- Astellas Pharma Global Development$22K
- Bristol Myers Squibb$9K
- Bayer$5K
- Otsuka Pharmaceutical Co., Ltd.$3K
What the payments were for
- Consulting fees$109,7016%
- Speaking & faculty fees$1,599,00388%
- Travel & lodging$66,7434%
- Food & beverage$40,5012%
- Education$1,0870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,817,035 in reported general payments places this provider in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 99 | $2,214,860 |
| JakafiRuxolitinib Phosphate | 70 | $1,183,063 |
| XpovioSelinexor | 31 | $950,324 |
| ImbruvicaIbrutinib | 45 | $714,344 |
| RevlimidLenalidomide | 27 | $478,104 |
| VonjoPacritinib Citrate | 18 | $461,187 |
| Lenalidomide | 31 | $445,676 |
| SprycelDasatinib | 20 | $349,156 |
| CalquenceAcalabrutinib Maleate | 22 | $340,683 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $326,815 |
| OnuregAzacitidine | 14 | $309,002 |
| IclusigPonatinib Hcl | 15 | $284,467 |
| PromactaEltrombopag Olamine | 13 | $168,672 |
| VenclextaVenetoclax | 45 | $161,640 |
| BesremiRopeginterferon Alfa-2b-Njft | 12 | $101,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel, Onureg | $173,029 | $2,873,018133 claims |
| Incyte CorporationJakafi | $440,087 | $1,183,06370 claims |
| Karyopharm Therapeutics Inc.Xpovio | $141,623 | $950,32431 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $4,937 | $714,34445 claims |
| Bristol Myers SquibbRevlimid | $10,449 | $478,10427 claims |
| AstraZenecaCalquence | $380 | $340,68322 claims |
| GSKOjjaara | $52,750 | $326,81512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $50,959 | $284,46715 claims |
| NovartisPromacta | $2,712 | $168,67213 claims |
| AbbVieVenclexta | $65,294 | $161,64045 claims |
| Pharmaessentia USA CorporationBesremi | $94,174 | $101,21412 claims |
| PfizerBosulif, Eliquis | $74,785 | $76,54224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
- Marcel DevettenOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.